Navigation Links
Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
Date:1/13/2011

ERIE, Pa., Jan. 13, 2011 /PRNewswire/ -- Kanzius Cancer Research Foundation ("KCRF") announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.  The manuscript illustrates how Drs. Steven A. Curley and Evan S. Glazer's studies prove that radiofrequency fields can treat pancreatic tumors, which today, kill more than 95% of diagnosed patients. Studies found that noninvasive radiofrequency (RF) fields were effective in controlling relatively large malignant pancreatic tumors.  Additionally, this process took place without any injury to surrounding tissue or changes in non-human subject behavior.

(Photo: http://photos.prnewswire.com/prnh/20110113/NE30158 )

The manuscript describes the process as non-human subjects are exposed to 10 minutes of nonionizing radiofrequency (RF) radiation followed by 36 hours of treatment using targeted gold nanoparticles (AuNP). This revolutionary design shows that the Kanzius RF machine alongside these particular nanoparticles create an effective formula for controlling pancreatic cancer cells.  

"John Kanzius, who created the RF device, once envisioned a cancer treatment that would be both effective and have zero side effects," remarked Curley, Chief of Gastrointestinal Tumor Surgery and Program Director of Multidisciplinary Gastrointestinal Cancer Care at The University of Texas M. D. Anderson Cancer Center. "These experiments demonstrate that the Kanzius RF device controls pancreatic cancer cells without any damage to nearby cells, or normal tissues and organs. We still have a lot of work to do but this is an important proof of principle."

"Every day, our team at the Kanzius Cancer Research Foundation works to help fund this incredible research," said Mark Neidig, Executive Director of KCRF. "These recent findings bring us one step closer to producing an effective, noninvasive cancer treatment that doesn't have the side effects associated with current treatments like chemotherapy and radiation."

This manuscript "Noninvasive Radiofrequency Field Destruction of Pancreatic Andenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles" can be found using this link: http://www.kanziuscancerresearch.org/research/published_research_manuscripts.

About the Kanzius Cancer Research Foundation

The Kanzius Cancer Research Foundation is a 501(c)(3) non-profit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses to human trials. The goal of KCRF is to raise money to support ongoing research grants.  Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic and prostate cancers. John Kanzius' sophisticated radio transmission machine is being manufactured in Erie, Pa.  For more information about the Kanzius research, visit www.Kanzius.org.


'/>"/>
SOURCE Kanzius Cancer Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
4. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
5. Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
6. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
7. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
8. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
9. Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
10. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
11. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. Ltd. ... KRW (US $18.9M) Series A financing. This financing round ... Tech Venture and SNU Bio Angel. This new funding ... billion KRW (US $27.7M) since its founding in 2015. ... bolster the development and commercialization of its immuno-oncology programs, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
Breaking Biology News(10 mins):